Rigshospitalet
Department of Radiation Biology
Thomas Urup, MD, Ph.d.student
Department of Radiation Biology,
The Finsencenter, Section 6321
Copenhagen University Hospital,
Blegdamsvej 9
DK - 2100 Copenhagen
 
Email: thomas.urup@regionh.dk
Phone:  (+45) 35 45 63 31
Fax: (+45) 35 45 63 01

Date of Birth:
April 18th, 1982
 
Current Position: 

MD. Ph.D. 

Education:
Medical Doctor, 2009

 

Research and Professional Experiences:
1998-2001High School diploma, Silkeborg High School
2002-2009Medical student, Aarhus university
2006-2006Locum doctor, Department of Haematology, Medical Center, Aalborg Hospital, Aarhus University Hospital
2006-2007Research student, Department of Haematology, Medical Center, Aalborg Hospital, Aarhus University Hospital
2009-2009Resident physician, Department of Oncology, Aalborg Hospital, Aarhus University Hospital
2009-2009Resident physician, Department of Infectious Diseases, Medical Center, Aalborg Hospital, Aarhus University Hospital
2009-2010Resident physician, General Medicine, Aalborg
2010- 2010Research assistant, Department of Haematology, Medical Center, Aalborg Hospital, Aarhus University Hospital
2010 -2011Resident physician, Department of Haematology, Medical Center, Aalborg Hospital, Aarhus University Hospital 
2011-2012Resident physician, Department of Oncology, The Finsencenter, Copenhagen University Hospital 
2012-2013Research assistant, Department of Radiation Biology, The Finsencenter,
Copenhagen University Hospital
2013-2016Ph.d. student, Department of Radiation Biology, The Finsencenter, Rigshospitalet, Copenhagen University Hospital
2016-Research assistant, Department of Radiation Biology, The Finsencenter, Rigshospitalet, Copenhagen University Hospital
   
Relevant courses:
2006Clinical cancer science, Clinical statistics and epidemiology in Oncology, DAFKO, Aarhus University Hospital
2011Danish Haematology Graduate School PhD Course 2011, Aarhus University Hospital
2011Good Clinical Practice (GCP) course, Aalborg Hospital, Aarhus University Hospital
2012Radiation Therapy Course, Aarhus University Hospital
2013Course in Laboratory Animal Science, FELASA kategori C, Department of Experimental Medicine, Copenhagen University
2013Responsible Conduct of Research, Copenhagen University
2013Basic Statistics, Copenhagen University
2013Clinical Cancer Research 2013, Copenhagen University
2013Introduction course to SPSS, Copenhagen University
2014Tumor Biology Course, Copenhagen University
2014The National Annual PhD course in Oncology/Hematology, Nyborg
        
Conferences and Meetings:
20104th European Myeloma Academy, Berlin
2010American Society of Haematology (ASH) 52nd Annual Meeting, Orlando
2011Danish Haematology Graduate School PhD Course 2011, Hindsgavl
2012EBCC 2012: European Breast Cancer Conference 2012, Vienna
2012Post American Society of Clinical Oncology (ASCO), Copenhagen
2013The 15th International Symposium on Anti-Angiogenic Therapy, San Diego
2013Danish Society for Cancer Research, 26th meeting, Vilvorde
2015Danish Society for Cancer Research, 28th meeting, Vilvorde
2016Danish Society for Cancer Research, 29th meeting, Vilvorde (Oral)
2016Scandinavian Society of Neuro-Oncology, 2016 Copenhagen (Oral)
 
Oral Presentation:
2015XI Northern Lights, Neuroscience Symposium on Brain Tumors, Middelfart: Urup T, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Poulsen HS, Lassen U: Clinical variables serve as prognostic factors in a model for bevacizumab re-sponse in recurrent glioblastoma multiforme
2015The 20th Annual SNO Scientific Meeting and Education Day, 2015 San Antonio, USA: Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U. Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients.
2015Dansk Neuro-Onkologisk Gruppe Årsmøde, Copenhagen: Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U. Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients.
2016Scandinavian Society of Neuro-Oncology Meeting, Copenhagen 2016: Urup T, Michaelsen SR, Staunstrup LM, Vitting-Seerup K, Bennedbæk M, toft A, Jønson L, Broholm H, Hamerlik P,Poulsen HS, Lassen U; Effect of bevacizumab combination therapy on transcriptional changes in responding and non-responding recurrent glioblastoma patients.
2016Danish Society for Cancer Research, 29th meeting, Vilvorde: Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U. Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients.
Poster Presentation:
2014Danish Society for Cancer Research, 27th meeting, Vilvorde: Urup T, Grunnet K Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Poulsen HS, Lassen U: A Prognostic Model for Clinical Response to Bevacizumab in Recurrent Glioblastoma
2014The European Association of Neuro-Oncology, 11th meeting, Torino: Urup T,Grunnet K, Christensen IJ, Michaelsen SR,Toft A, Broholm H, Kosteljanetz M, Lassen U,Poulsen HS:Variables Serve as Predictive Factors in a Model for Clinical Response to Bevacizumab in Recurrent Glioblastoma Multiforme
2015The Annual American Association for Cancer Research (AACR), Philadelghia, Pennsylvania, USA; Urup T, Grunnet K, Christensen IJ, Michaelsen SR, Toft Anders, Larsen VA, Broholm H, Kosteljanetz M, Poulsen HS, Lassen U: A Prognostiv Model for Clinical Response to bevacizumab in Recurrent Glioblastoma.
 2015The Annual American Association for Cancer Research (AACR), Philadelghia, Pennsylvania, USA; Urup T, Grunnet K, Christensen IJ, Michaelsen SR, Toft Anders, Larsen VA, Broholm H, Kosteljanetz M, Poulsen HS, Lassen U: A Prognostiv Model for Clinical Response to bevacizumab in Recurrent Glioblastoma.
     
Publications with peer review:
1.
Johnsen HE, Kjeldsen MK, Urup T, Fogd K, Pilgaard L, Boegsted M, Nyegaard M, Christiansen I, Bukh A, Dybkaer K.: Cancer stem cells and the cellular hiearchy in haematological malignancies. Eur J Cancer. 2009 Sep; 45 suppl l:194-201.Pubmed PMID: 19775618
2.Urup T, Madsen G, Hallager S, Schmitz A, Fogd K, Bøgsted M, Nyegaard M, Sørensen KD, Johnsen HE. Cancer stem cells in the haematopoietic system. Ugeskr Laeger. 2010 Sep 20;172(38):2597-600. Pubmed PMID: 20920402.
3.Urup T, Pawlak W, Petersen PM, Pappot H, Rørth M, Daugaard G. Treatment with taxotere and cisplatin in advanced adrenocortical carcinoma, a Phase II study.Br J Cancer. 2013 May 28;108(10):1994-7. Pubmed PMID: 23652308.
4.Poulsen HS, Urup T, Michaelsen SR, Staberg M, Villingshøj M, Lassen U: The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Manag Res.2014:6 373–387.Pubmed PMID: 25298738
5.Nedergaard MK, Michaelsen SR, Urup T, Broholm H, El Ali H, Poulsen HS, Stockhausen MT, Kjaer A and Lassen U: 18F-FET MicroPET and MicroMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma:PLoS One. 2015 Feb 13:10(2): e0115315. Pubmed PMID: 25680186
6.Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U: Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecants treated with bevacizumab and irinotecan. Acta Oncol 2015. Acta Oncol. 2016 Feb 1:1-5. PMID: 26828563.
7.Campos B, Olsen LR, Urup T, Poulsen HS. A Comprehensive Profile of Recurrent Glioblastoma.  Oncogene. 2016 Apr 4. doi: 10. PMID: 27041580.
8.Urup T, Michaelsen SR, Rønn Olsen LR,Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U: Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients. Molecular Oncology.Mol Oncol. 2016 Oct 10(8). PMID: 27262894.
9.Bergkvist KS, Nørgaard MA, Bøgsted M, Schmitz A, Nyegaard M, Gaihede M, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Urup T, El-Galaly TC, Madsen J, Bødker JS, Dybkær K, Johnsen HE. Characterization of memory B cells from thymus and its impact for DLBCL classification. Exp Hematol. 2016 Oct;44(10). PMID: 27297329.
10.Poulsen SH, Urup T, Grunnet K, Christensen IJ, Larsen VA, Jensen ML, Af Rosenschöld PM, Poulsen HS, Law I. The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2016 Aug. PMID: 27554774.
11.Urup T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, Bennedbæk M, Toft A, Olsen LR, Jønson L, Issazadeh-Navikas S, Broholm H, Hamerlik P, Poulsen HS, Lassen U. Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. BMC Cancer. 2017 Apr 18;17(1):278. doi: 10.1186/s12885-017-3251-3. PMID: 28420326
 
Articles submitted:
1.Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen AVA, Lassen U, Broholm H, Poulsen HS: Predictive and Prognostic Biomarkers in Recurrent WHO Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. Submitted
2.Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, Christensen IJ, Poulsen HS, Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients. Submitted.

 

 

 

The Finsencenter, Section 6321, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark